Dr. Lindsay Clark’s new study will evaluate the psychological consequences of disclosing amyloid test results to cognitively unimpaired adults. Dr. Clark joins the podcast to define amyloid accumulation and discuss how her study will examine the process of revealing amyloid results to research participants in Alzheimer’s disease research studies.
Guest: Lindsay Clark, PhD, assistant professor, University of Wisconsin School of Medicine and Public Health
Episode Topics:
1:13 - What is amyloid accumulation and its relationship to Alzheimer’s disease?
3:14 - How are you measuring amyloid in living people?
5:56 - Are newer methods like PET scans reliable?
6:20 - Do patients learn the results of these scans?
7:30 - Do research participants ever learn their results?
8:44 - Who is the target population for studying amyloid scans?
9:35 - Why does disclosing the results take so many careful considerations?
11:48 - What do you think are the components of a good disclosure?
14:16 - Are you disclosing specific numbers of the results?
16:31 - Why does your study focus on amyloid PET scan results?
18:33 - Do you believe the key concepts of disclosure can work with other biomarker studies?
Show Notes
Learn more about Dr. Clark's Amyloid Disclosure Study: [ Ссылка ]
Listen to another Dementia Matters episode on the topic of disclosing Alzheimer's disease risk to research participants, "The Power of Disclosure: How Explaining Risk of Alzheimer's Disease Impacts Life Afterward": [ Ссылка ]
Connect with us
Find transcripts and more at our website: [ Ссылка ]
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter: [ Ссылка ], [ Ссылка ]
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter: [ Ссылка ]
